Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{2f92c2ccbf1745dfa8feba94171d4784,
title = "The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment",
abstract = "Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.",
keywords = "Esophageal Stenosis, Humans, Intestinal Perforation, Male, Middle Aged, Proton Pump Inhibitors, Withholding Treatment, Zollinger-Ellison Syndrome",
author = "Pierre Poitras and Marie-H{\'e}l{\`e}ne Gingras and Rehfeld, {Jens F}",
note = "Copyright {\circledC} 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.",
year = "2012",
doi = "10.1016/j.cgh.2011.08.012",
language = "English",
volume = "10",
pages = "199--202",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B./Saunders Co",
number = "2",

}

RIS

TY - JOUR

T1 - The Zollinger-Ellison syndrome

T2 - dangers and consequences of interrupting antisecretory treatment

AU - Poitras, Pierre

AU - Gingras, Marie-Hélène

AU - Rehfeld, Jens F

N1 - Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

PY - 2012

Y1 - 2012

N2 - Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.

AB - Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.

KW - Esophageal Stenosis

KW - Humans

KW - Intestinal Perforation

KW - Male

KW - Middle Aged

KW - Proton Pump Inhibitors

KW - Withholding Treatment

KW - Zollinger-Ellison Syndrome

U2 - 10.1016/j.cgh.2011.08.012

DO - 10.1016/j.cgh.2011.08.012

M3 - Journal article

VL - 10

SP - 199

EP - 202

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -

ID: 36789907